

Validation of a New Portable Exhaled Nitric Oxide Analyzer, NIOX VERO[®]: Randomized Studies in Asthma

Kjell Alving · Robert Anolik · Glenn Crater · Craig F. LaForce ·
Kathy Rickard

Received: November 10, 2016

© The Author(s) 2017. This article is published with open access at Springerlink.com

ABSTRACT

Introduction: Fractional exhaled nitric oxide (FeNO) is a non-invasive marker of airway inflammation, and a new portable analyzer (NIOX VERO[®]) is now available. Our studies aimed to assess the agreement of measurements between NIOX VERO[®] and a reference device (NIOX MINO[®]) and assess the reproducibility of NIOX VERO[®].

Methods: Paired FeNO readings were obtained from 112 subjects from both devices to assess agreement and reproducibility. FeNO readings

were obtained from 122 subjects using NIOX VERO[®] to assess inter-operator repeatability. All subjects had a diagnosis of asthma and were aged ≥ 7 years.

Results: Agreement was shown with 90.8% of subjects within tolerance limits for the first valid FeNO measurement. Mean observed paired difference for the first valid FeNO measurement on each device was -4.6 ppb [95% confidence interval (CI) -5.825 to -3.377 ; $p < 0.0001$]. Weighted Deming Regression Analysis showed a slope of 0.842 (95% CI 0.757 , 0.927) and a γ -intercept of -0.472 (95% CI -1.999 , 1.055). Paired differences were centered close to 0. Intra-subject repeatability of NIOX VERO[®] was significantly better than NIOX MINO[®] ($p = 0.0112$). Further, inter-operator repeatability was achieved with NIOX VERO[®] with a mean intra-subject variance of 6.61 ± 17.954 ppb (upper 95% CI 9.41) and an estimated standard deviation of 2.57 (upper 95% CI 3.07). The coefficient of variance was 0.066 ± 0.054 (upper 95% CI 0.074).

Conclusion: Our findings show that the portable instrument NIOX VERO[®] is clinically equivalent to NIOX MINO[®] when used in an asthma population. The NIOX VERO[®] analyzer gives reproducible, consistent measurements that are well within the technical specifications of the device, showing no observable pattern of a training effect or operator-order effect on FeNO results. Thus, our findings validate the NIOX VERO[®].

Funding: Aerocrine AB, Solna, Sweden.

Enhanced content To view enhanced content for this article go to <http://www.medengine.com/Redeem/BC87F0600B0A5026>.

Electronic supplementary material The online version of this article (doi:[10.1007/s41030-017-0032-8](https://doi.org/10.1007/s41030-017-0032-8)) contains supplementary material, which is available to authorized users.

K. Alving
Department of Women's and Children's Health,
Uppsala University, Uppsala, Sweden

R. Anolik
Allergy and Asthma Specialists, PC, Blue Bell, PA,
USA

G. Crater · K. Rickard (✉)
Circassia Pharmaceuticals Inc., Morrisville, NC, USA
e-mail: Kathy.Rickard@circassia.com

C. F. LaForce
North Carolina Clinical Research, Raleigh, NC, USA

Keywords: Asthma; Inter-device comparison; NIOX VERO®; NIOX MINO®; Nitric oxide; Randomized; Reproducibility

INTRODUCTION

Exhaled nitric oxide (NO) originates primarily in bronchial epithelial cells. NO is an excellent surrogate marker of inhaled corticosteroid (ICS)-sensitive local type-2 cytokine-driven inflammatory mechanisms, which are of central importance in allergic airway inflammation [1–4].

The detection of NO in exhaled air was first reported in 1991 [5], and was later shown to be elevated in exhaled air from patients with asthma [6]. Measuring the fraction of exhaled NO (FeNO) offers the only simple, non-invasive and objective method of assessing local airway inflammation in asthma [1, 7, 8]. FeNO is now an established biomarker for airway inflammation and is strongly recommended by the American Thoracic Society (ATS) for the diagnosis and management of asthma [9].

FeNO is easily measured in a clinical setting using handheld or stationary analyzers [10]. The ideal analyzer is portable and easy to use with good reproducibility and reliability regardless of patient baseline FeNO, age, or operator expertise [11]. NIOX VERO® and NIOX MINO® are two such handheld electrochemical analyzers, which enable rapid and cost-effective assessment of airway inflammation in asthma at the point of care. Furthermore, the testing is easy to perform and requires minimal training for the operator to use. The assessment cannot be influenced by patient effort or variations in the clinician's technique. NIOX MINO® and NIOX VERO® do not require calibration at the clinic, while built-in controls and external quality control procedures warrant reliability of measured values. Both devices can be used by patients aged 4 years and older in the European Union (EU) and patients aged 7 years and older in the United States (US). NIOX VERO® contains significant improvements learned from years of making and using electrochemical

sensors for the measurement of exhaled nitric oxide. When compared with NIOX MINO®, enhancements to NIOX VERO® include its use without being connected to a power supply and improved visibility of the display screen. In addition, NIOX VERO® has an ergonomic handle to aid portability.

In this paper, we describe the outcomes of four studies performed to validate the NIOX VERO® analyzer.

METHODS

Agreement between NIOX MINO® and NIOX VERO® was investigated in two studies, AER-045 and AER-048 (AER-045/048). Repeatability of FeNO measured with NIOX VERO® using different operators was also evaluated across two studies, TV-014 and TV-018 (TV-014/018). AER-045 and AER-048 share the same methodology, as do TV-014 and TV-018 with the exception that AER-048 and TV-018 also aimed to enrol a proportion of patients with higher FeNO (>40 ppb). Since the second studies are extensions of the first two, only the pooled data from each pair of studies are presented in this article.

The studies were approved by the local Institutional Review Board and were conducted in compliance with Good Clinical Practice and the Declaration of Helsinki. All subjects provided written consent, or legal guardians provided written assent, prior to any study procedures being performed. In each study, subjects attended the clinic once for study-specific assessments.

Study Design

AER-045/048 were multi-center, open-label, randomized, single-visit, controlled studies to compare FeNO measured with NIOX VERO® and NIOX MINO®. TV-014/018 comprised multi-center, randomized, single-visit, point-of-care studies to assess inter-operator variability of NIOX VERO®. Further details are given in the online supplement.

Participants

Subjects

Males and females were enrolled aged 7 years or over with physician-diagnosed asthma [or were under evaluation for asthma (AER-045)] and able to perform FeNO measurements using the study analyzer(s). Subjects who did not refrain from taking food, drink, nicotine or strenuous exercise within 1 h of the FeNO assessments or who had any other pulmonary disease or acute respiratory illness or sinusitis were excluded. For AER-045, subjects were excluded with severely impaired lung function (predicted FEV₁ <50%), diagnosed lung cancer or other active pulmonary infectious disease, including tuberculosis.

For AER-048 only, subjects were included if they had risk factors for elevated FeNO (>50 ppb) or they had current respiratory symptoms such as cough, wheeze, and/or dyspnea or a history of non-compliance with prescribed asthma treatment. In addition, subjects were only included in the AER-048 if they had a FeNO of >40 ppb on the study day.

Operators

Operators were male and female physicians, nurses, respiratory therapists or laboratory technicians already familiar with NIOX MINO[®] (TV-014/018).

Devices

NIOX VERO[®] (Aerocrine, Sweden) was under development at the time of the study in the US and was subsequently cleared by the FDA in November 2014. The analyzer was used according to the Investigator User Manual [12]. NIOX MINO[®] (Aerocrine) is CE marked and cleared for clinical use in the US by the FDA, and was used according to the User Manual [13].

Assessments

In all studies, FeNO measurements were obtained using a standard technique—single breath online, 10-s exhalation in accordance with current recommendations [14]. If a valid

FeNO assessment was not achieved after 10 attempts, the measurement was considered unsuccessful and the subject was discharged from the study. Data from all valid FeNO measurements for all subjects were analyzed. In AER-045/048, subjects attempted a total of two valid exhalations (maximum of six exhalations) at a fixed flow rate (50 mL/s) with each device. The order in which the devices were used was randomized. An evaluable subject successfully completed four valid FeNO measurements, two with each device, within approximately 30 min.

Adverse events (AEs) and serious injuries were assessed from the time of informed consent/assent and during the study visit for each subject (not for operators). Further details are provided in the online supplement.

Statistical Methods

Statistical Analyses

Two-sided tests were used for all analyses; 95% confidence intervals (CI) were calculated and a *p* value ≤0.05 was considered statistically significant. Statistical analyses were processed using SAS v.9.2.

AER-045/048

Agreement between the first valid FeNO measurements from the two devices was confirmed if the lower limit of the one-sided 95% CI of the proportion of patients within the tolerance limits was ≥0.90. Differences of <10 ppb for absolute values <50 ppb and of <20% for those >50 ppb were considered within tolerance limits. A clinically significant change in FeNO is considered to be >10 ppb (or 20%) [9], so device differences within these limits were considered clinically non-significant. Normal approximation was used to calculate the CI when the observed proportion (*p*) and 1 – *p* was >5/*n* [15], otherwise the exact CI was calculated.

Agreement was also analyzed between first valid FeNO measurements from the two devices and evaluation of the mean differences between mean values from each device using Bland–Altman plots. Intra-individual values and mean values of FeNO measurements from each device were evaluated using 95% limits of

agreement, Weighted Deming Regression analysis, and scatter plots with regression lines.

Repeatability was assessed by analyzing the differences between mean intra-subject standard deviation (SD) of duplicate FeNO measurements from each device using the Wilcoxon Signed Rank Test.

TV-014/018

Repeatability was measured using NIOX VERO[®] when three consecutive valid FeNO measurements were obtained from one subject by three different operators using the same device; assessment was based on NCCLS EP5-A2 guidance [16]. Intra-subject variation was obtained for each subject and the coefficient of variance (CV) was calculated. The intra-subject variance, CV and upper one-sided 95% CI were generated for each measure. Summaries were provided for subjects with mean FeNO <50 ppb and those with mean FeNO ≥50 ppb. In TV-018, enrollment was stratified for subjects with FeNO >40 ppb based on their first FeNO value.

Details of additional analyses and any changes in the planned analyses are provided in the online supplement.

Analysis Populations

In AER-045/048, efficacy analyses were performed using subjects with ≥1 valid measurement using NIOX MINO[®] and NIOX VERO[®] (Efficacy Subjects population) and the All Subjects population was used for all other analyses. In TV-014/018, subjects completing three FeNO measurements were included in the Efficacy Subjects population.

Sample Size

Ninety evaluable subjects were planned to give >80% power to demonstrate that the lower limit of a 90% CI was ≥0.90. This was based on the hypothesis that the true proportion within tolerance limits was 0.97 (AER-045), with an extra 20–30 subjects planned and stratified by baseline FeNO level to give 10 subjects with FeNO >40 and <50 ppb, and 10–20 subjects with FeNO ≥50 ppb (AER-048).

Between 80 and 90 subjects were planned, based on the expected precision for the

estimated intra-subject variance for subjects with valid FeNO values to obtain approximately 20 subjects with FeNO values ≥50 ppb (TV-014); a minimum sample size of 20 was planned given the one-sided upper bound of the SD was 1.18 in order to establish relative variance estimates for subjects with FeNO >40 ppb (TV-018).

Approximately 40 operators were planned with the number of operators per site based on the number of planned subjects. Each set of 3 operators was allowed to make only one assessment together, no pair of operators conducted more than three assessments together, and no operator was allowed to make more than eight assessments.

RESULTS

Participants

Subject demographics are presented in Table 1. Of the 112 subjects enrolled, 8 (7.1%) did not complete the AER045/048 studies: 4 (3.6%) did not complete the two approved exhalations using NIOX VERO[®] within the maximum number of attempts allowed; 1 (0.9%) experienced NIOX VERO[®] instrument failure; and 3 (2.7%) had a FeNO concentration <5 ppb. All subjects completed the TV-014/018 studies.

In TV-014/018, 54 operators were employed, all female, with a mean (SD) age of 48.5 (13.85) years with the largest proportion trained as registered nurses (46.3%), or as licensed practical nurses/associated nursing degree (20.4%) (Supplementary Table 1).

No AEs, serious injuries, issues or problems were reported with use of either device.

Further details are provided in the online supplement.

Device Comparisons

Agreement

The primary objective of the study, showing that the 95% CI for the proportion of subjects within the tolerance limits was above 0.90, was not met when comparing NIOX MINO[®] and NIOX VERO[®] (Table 2). The mean

Table 1 Demographics, pooled for studies AER-045 and AER-048 and for studies TV-014 and TV-018

	AER-045/048	TV-014/018
Number of subjects enrolled	112	122
Number of subjects randomized to MINO:VERO device sequence	56 (50)	NA
Mean age (SD), years	28.7 (18.56)	34.3 (17.91)
Sex, <i>n</i> (%), male	54 (48.2)	53 (43.4)
Asthma, <i>n</i> (%)	112 (100)	64 (52.5)
Efficacy subjects		
# with 1 valid FeNO measurement on each device, <i>n</i> (%)	109 (97.3)	NA
# with 2 valid FeNO measurements on each device, <i>n</i> (%)	107 (95.5)	NA

FeNO fractional exhaled nitric oxide, SD standard deviation, NA not applicable

Table 2 Summary of the number and proportion of subjects within the tolerance limits for first valid and mean FeNO measurement; pooled data for studies AER-045 and AER-048 (Efficacy Subjects)

	AER-045/048	
	First valid FeNO measurement	Mean FeNO measurement
Number of subjects in analysis	109	109
Number with tolerance limits	99	98
Proportion within tolerance limits	0.908	0.899
Lower limit of a 95% CI	0.838	0.827

CI confidence interval, FeNO fractional exhaled nitric oxide

overall observed paired difference (SD) between the devices in relation to the mean first valid FeNO was -4.6 (6.45) ppb equating to a mean percent difference of -13.2% (33.95). The mean observed paired difference in average results (NIOX VERO[®] – NIOX MINO[®]) was -4.6 ppb (95% CI -5.825 to -3.377 ; $p < 0.0001$) (Fig. 1). The slope of the Weighted Deming Regression Analysis plot of first valid FeNO values was 0.842 (95% CI 0.757 , 0.927) with a γ -intercept of -0.472 ppb (95% CI -1.999 , 1.055) (Fig. 2).

Evaluation of the mean differences in mean FeNO values obtained from each device gave a mean observed difference in average results (NIOX VERO[®] – NIOX MINO[®]) of -4.5 ppb (95% CI -5.635 to -3.449 ; $p < 0.0001$). Similar results were seen with the mean of the average FeNO measurement on each device: the Weighted Deming Regression analysis slope was 0.929 (95% CI 0.854 , 1.033) and γ -intercept was

-2.418 ppb (95% CI -3.861 , -0.974). FeNO measurements using NIOX VERO[®] were slightly lower than those using NIOX MINO[®] by approximately 3 ppb, which remained within the technical specifications of the devices (± 5 ppb).

Reproducibility

Intra-subject repeatability was demonstrated for both devices, with significantly better repeatability achieved with NIOX VERO[®] than NIOX MINO[®] (median 0.25 vs, 1.00 , respectively; $p = 0.0112$) (Table 3).

Inter-operator Repeatability

Inter-operator repeatability was achieved using the NIOX VERO[®]. Pooled mean intra-subject variance was 6.61 ± 17.954 ppb (upper 95% CI




Fig. 1 Bland Altman Plot results for the first valid FeNO measurement on each device (NIOX VERO[®] and NIOX MINO[®]) showing pooled study data from studies AER-045 and AER-048 (Efficacy Subjects)




Fig. 2 Observed results for first valid FeNO measurement on both devices (NIOX VERO[®] and NIOX MINO[®]) for pooled study results from study AER-045 and AER-048 (Efficacy Subjects)

9.41) with an estimated SD of 2.57 (upper 95% CI 3.07). The CV was 0.066 ± 0.054 (upper 95% CI 0.074) (Fig. 3a, b; Supplementary Table 2).

There was no observed operator-order effect on the FeNO results. Post hoc repeated analysis of variance (ANOVA) showed mean FeNO

Table 3 Intra-subject variance for efficacy subjects with two valid FeNO measurements on each device to show repeatability (Efficacy Subjects)

Intra-subject variance	NIOX VERO [®]	NIOX MINO [®]	Paired differences
Mean (SD)	4.79 (23.701)	4.87 (9.292)	−0.08 (25.166)
Median	0.25	1.00	−0.025
Min, max	0.00, 240.25	0.00, 56.25	−47.25, 238.00

SD standard deviation

values were similar between all three operators, but, due to the large sample size, small but statistically significant differences were noted ($p < 0.05$) (Table 4; Supplementary Fig. 1a–c).

Post hoc Weighted Deming Regression on the three pairs of observations gave an estimated bias <2% for all pairs (estimated percent bias close to 1%; estimated average bias between −1.00 and 1.20% depending on the pairs assessed).

Categorical FeNO values were consistent and repeatable for all subjects. For FeNO <50 ppb, mean intra-subject variance was 1.37 ± 2.136 (upper 95% CI 1.77), with an estimated SD of 1.17 (upper 95% CI 1.33) and CV of 0.072 ± 0.058 (upper 95% CI 0.082). For FeNO ≥ 50 ppb, mean intra-subject variance was 21.97 ± 30.976 (upper 95% CI 31.64), with an estimated SD of 4.69 (upper 95% CI 5.62) and CV of 0.048 ± 0.036 (upper 95% CI 0.060).


DISCUSSION

In our studies, FeNO values were obtained using two electrochemical exhaled NO analyzers, NIOX MINO[®] and NIOX VERO[®]. The subject population included adults and children with asthma and was representative of asthma patients in the US and EU [17]. These were the first studies to compare NIOX VERO[®] with NIOX MINO[®] and showed a clinically acceptable agreement between the devices with a significant improvement in reproducibility with NIOX VERO[®] compared to the reference device. While there was a statistically significant difference between the two analyzers, the differences were small and are unlikely to be of clinical significance in the care of patients. The


same agreement was seen when comparing the first valid measurement and the mean of two measurements. Although FeNO measurements using the NIOX VERO[®] were slightly lower than those using the NIOX MINO[®] (by approximately 3 ppb) they were highly correlated and the difference was within the technical specification of the instrument (± 5 ppb).

To date, NIOX MINO[®] has been compared with three chemiluminescence NO analyzers, the NIOX[®], Ecomedics and Sievers NOA280i [18–30]. All these studies showed agreement between the FeNO values obtained with the devices being studied, with a clinically acceptable level of agreement shown with NIOX [19–22, 25, 26] and Ecomedics [29]. NICE have also reviewed evidence from studies comparing NIOX MINO[®] and NIOX VERO[®] with chemiluminescence analyzers to establish whether these devices could be considered equivalent [31]. Some differences were observed, and equivalence seemed poorer under certain circumstances, such as in patients with higher FeNO levels. However, there was generally a good correlation seen for NIOX VERO[®] and NIOX MINO[®] with other chemiluminescence analyzers so that these devices are considered broadly equivalent [31].

Intra-subject repeatability was acceptable for both devices with significantly better repeatability shown for NIOX VERO[®] than NIOX MINO[®]. FeNO measurements using NIOX VERO[®] were reproducible, consistent and well within the technical specifications of the device. Our findings correlate with previous observations with NIOX MINO[®]; other studies in adults and children have reported excellent reproducibility when using this device [11, 21, 22, 25, 29, 30, 32, 33]. However, poor



Note: Subjects with a FeNO measurement recorded as < 5 ppb were considered to have a FeNO measurement = 5 ppb.
 Note: Dashed lines represent lines of slope = 1.2 and 0.8.



Note: Subjects with a FeNO measurement recorded as < 5 ppb were considered to have a FeNO measurement = 5 ppb.
 Note: Dashed lines represent lines of slope = -0.2 and 0.2.

◀**Fig. 3 a** Individual FeNO measurements versus subject mean FeNO for pooled study data from studies TV-014 and TV-018; **b** individual FeNO measurements: subject mean FeNO for pooled study data from studies TV-014 and TV-018 (Efficacy Subjects). Both figures provide evidence for inter-operator repeatability using NIOX VERO®

reproducibility was seen in one study of NIOX MINO® specifically in children and teenagers, but only when comparing absolute FeNO values—reproducibility was acceptable when FeNO values were categorized as low, normal, intermediate or high [19].

Our findings showed no observable pattern of a training effect or order effect on FeNO results when measured three times using NIOX VERO® by three different operators. These results support the feasibility of using NIOX VERO® at the point of care and are consistent with those seen using NIOX MINO®. Gill et al. [11] showed close agreement between replicate operator measures for NIOX MINO®; mean within-subject SD in 17 subjects with FeNO

<30 ppb was 1.15 (95% CI 0.67–1.53) which was below the set limit of 3 ppb. In the three subjects with FeNO >30 ppb, the mean within-subject coefficient of variation was 2.4 and below the hypothesis limit of 10 [11].

How did higher FeNO affect our results? In TV-014/018, increased variability between measurements was seen as the average subject FeNO value increased, but the CV appeared to remain relatively constant across the range of measured values. Furthermore, values were consistently within 20% of their overall mean and all pairs were within 10 ppb for values with an overall mean <50 ppb. With regards to statistical considerations, there was no evidence of bias across the three operator assessments as confirmed by Weighted Deming Regression and ANOVA. Variability did increase in time and a few pairs of high values differed by >20%, although in these cases it would not have affected the ≥50 ppb assessment, and the CV was similar among the data cuts considered. Further, across all studies, NIOX MINO® and NIOX VERO® were shown to be safe in subjects with high FeNO.

Table 4 FeNO results by operator order and site by mean subject FeNO value for pooled study data from studies TV-014 and TV-018 (Efficacy Subjects)

	Operator (1)			All observations	ANOVA <i>p</i> value
	1st operator	2nd operator	3rd operator		
Subjects with FeNO <50 ppb					
<i>n</i>	91	91	91	273	0.9979
Mean (SD)	15.0 (10.44)	15.1 (10.77)	15.0 (10.99)	15.0 (10.70)	
Median	12.0	11.0	10.0	11.0	
Min, max	5, 47	5, 47	5, 50	5, 50	
Subjects with FeNO ≥50 ppb					
<i>n</i>	31	31	31	93	0.8006
Mean (SD)	76.5 (28.35)	80.6 (29.34)	81.0 (30.52)	79.4 (29.17)	
Median	69.0	72.0	72.0	71.0	
Min, max	49, 163	52, 174	49, 173	49, 174	

ANOVA analysis of variance, FeNO fractional exhaled nitric oxide, *max* maximum, *min* minimum, *SD* standard deviation

Study Strengths and Limitations

These were one-visit studies that were simply designed in order to evaluate technical validation of the devices. More visits over time would have demonstrated how NIOX VERO[®] can measure changes due to both inter-operator and biological variability.

CONCLUSION

Our findings have shown that the NIOX MINO[®] and new NIOX VERO[®] analyzers are clinically equivalent when used in an asthma population representative of that seen in the US and EU. Furthermore, we have shown that FeNO measurements taken using the NIOX VERO[®] analyzer are reproducible, consistent and well within the technical specifications of the device, showing no observable pattern of a training effect or operator-order effect on FeNO results. Thus, our findings validate the portable NIOX VERO[®], enabling its clinical use in both children and adults.

ACKNOWLEDGEMENTS

These studies and the article processing charges were funded by Aerocrine AB, Solna, Sweden. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript. They take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published. Editorial assistance in the preparation of this manuscript was provided by Dr. Kathryn White of Cathean Ltd medical writing services. Support for this assistance was funded by Aerocrine Inc.

Disclosures. Kjell Alving is a former employee of Aerocrine AB (until March 2014) and has received research funding from this company. Kathy Rickard is an employee of Circassia Pharmaceuticals Inc (formerly Aerocrine Inc). Glenn Crater was an employee of Aerocrine Inc at the time of the study. Robert Anolik and

Craig F. LaForce both received grants from Aerocrine Inc to conduct the described studies but have nothing further to disclose.

Compliance with Ethics Guidelines. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all subjects for being included in the studies.

Data Availability. The datasets generated during and/or analyzed during the current study are not publicly available due the fact that it did not fall under the FDAAA 2007 requirements to publically disclose the data, but data are available from the corresponding author on reasonable request.

Open Access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

REFERENCES

1. Hanson JR, De Lurgio SA, Williams DD, Dinakar C. Office-based exhaled nitric oxide measurement in children 4 years of age and older. *Ann Allergy Asthma Immunol.* 2013;11:358–63.
2. Mahr TA, Malka J, Spahn JD. Inflammometry in pediatric asthma: a review of fractional exhaled nitric oxide in clinical practice. *Allergy Asthma Proc.* 2013;34:210–9.
3. Ludviksdottir D, Diamant Z, Alving K, Bjermer L, Malinovschi A. Clinical aspects of using exhaled NO in asthma diagnosis and management. *Clin Respir J.* 2012;6:193–207.
4. Bjermer L, Alving K, Diamant Z, et al. Current evidence and future research needs for FeNO

- measurement in respiratory diseases. *Respir Med.* 2014;108:830–41.
5. Gustafsson LE, Leone AM, Persson MG, Willund NP, Moncada S. Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. *Biochem Biophys Res Commun.* 1991;181:852–7.
 6. Alving K, Weitzberg E, Lundberg JM. Increased amount of nitric oxide in exhaled air of asthmatics. *Eur Respir J.* 1993;6:1368–70.
 7. Baraldi E, Filippone M. Inhaled corticosteroids in children. *N Engl J Med.* 2006;355:625.
 8. Buchvald F, Baraldi E, Carraro S, et al. Measurements of exhaled nitric oxide in healthy subjects age 4 to 17 years. *J Allergy Clin Immunol.* 2005;115:1130–6.
 9. Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FE_{NO}) for clinical applications. *Am J Respir Crit Care Med.* 2011;184:602–15.
 10. Dinakar C. Exhaled nitric oxide in pediatric asthma. *Curr Allergy Asthma Rep.* 2009;9:30–7.
 11. Gill M, Graff GR, Adler AJ, Dweik RA. Validation study of fractional exhaled nitric oxide measurements using a handheld monitoring device. *J Asthma.* 2006;43:731–4.
 12. NIOX VERO Investigational User Manual 2014.
 13. NIOX MINO User Manual November 2013.
 14. ATS, ERS. ATS/ERS recommendations for standardized procedures for online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. *Am J Respir Crit Care Med.* 2005;171:912–30.
 15. Altman DG. *Practical statistics for medical research.* Boca Raton, FL: CRC; 1990.
 16. Tholen DW, Kallner A, Kennedy JW, Krouwer JS, Meier K. Evaluation of precision performance of quantitative measurement methods; approved guideline. 2nd ed. CLSI document EP5-A2. Clinical and Laboratory Standards Institute, Wayne; 2004.
 17. See KC, Christiani DC. Normal values and thresholds for the clinical interpretation of the exhaled nitric oxide levels in the US General Population. Results from the National Health and Nutrition Examination Survey 2007–2013. *Chest.* 2013;143:107–16.
 18. Kim S-H, Moon J-Y, Kwak HJ, et al. Comparison of two exhaled nitric oxide analyzers: The NIOX MINO hand-held electrochemical analyser and the NOA280i stationary chemiluminescence analyser. *Respirology.* 2012;17:830–4.
 19. Selby A, Clayton B, Grundy J, et al. Are exhaled nitric oxide measurements using the portable NIOX MINO repeatable? *Respir Res.* 2010;11:43–51.
 20. Hemmingsson T, Linnarsson D, Gambert R. Novel hand-held device for exhaled nitric oxide analysis in research and clinical applications. *J Clin Monit Comput.* 2004;18:379–87.
 21. Alving K, Janson C, Nordvall L. Performance of a new hand-held device for exhaled nitric oxide measurement in adults and children. *Respir Res.* 2006;7:67–73.
 22. McGill C, Malik G, Turner SW. Validation of a hand-held exhaled nitric oxide analyser for use in children. *Pediatr Pulmonol.* 2006;41:1053–7.
 23. Vahlkvist S, Sinding M, Skamstrup K, Bisgaard H. Daily home measurements of exhaled nitric oxide in asthmatic children during natural birch pollen exposure. *J Allergy Clin Immunol.* 2006;117:1272–6.
 24. Chen W, Purohit A, Barnig C, Casset A, de Blay F. Niox and Niox Mino: comparison of exhaled NO in grass pollen allergic adult volunteers. *Allergy.* 2007;62:571–2.
 25. Khalili B, Boggs PB, Bahna SL. Reliability of a new hand-held device for the measurement of exhaled nitric oxide. *Allergy.* 2007;62:1171–4.
 26. Menzies D, Nair A, Lipworth BJ. Portable exhaled nitric oxide measurement: comparison with the “gold standard” technique. *Chest.* 2007;131:410–4.
 27. Pizzimenti S, Bugiani M, Piccioni P, et al. Exhaled nitric oxide measurement: correction equation to compare hand-held device to stationary analyser. *Respir Med.* 2008;102:1272–5.
 28. Prado OS, Ruiz AA, Murua JK, Aramburu JM, Knorr JIE, Pérez-Yarza EG. Concordancia entre dos dispositivos de medida de óxido nítrico exhalado. *An Pediatr (Barc).* 2007;67:572–7.
 29. Schiller B, Hammer J, Barben J, Trachsel D. Comparability of a hand-held nitric oxide analyser with online and offline chemiluminescence-based nitric oxide measurement. *Pediatr Allergy Immunol.* 2009;20:679–85.
 30. Kalliola S, Malmberg P, Rito T, Pelkonen AS, Mäkelä M. Can we use portable nitric oxide analyser in

-
- young children? *Pediatr Pulmonol.* 2011;46:627–31.
31. National Institute for Health and Care Excellence. Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath. NICE diagnostics guidance 12. 2014.
32. Takalo R, Piirilä P, Sovijärvi ARA. Repeatability of successive measurements with a portable nitric oxide analyser in patients with suggested or diagnosed asthma. *Scand J Clin Lab Investig.* 2008;68:830–2.
33. Taylor DR, Palmay R, Cowan JO, Herbison GP. Long term performance characteristics of an electrochemical nitric oxide analyser. *Respir Med.* 2011;105:211–7.